The Phase 1b/2a BEACON study is evaluating multiple ascending doses of subcutaneous briquilimab as a treatment for adult chronic spontaneous urticaria patients who remain symptomatic after high dose antihistamines and treatment with, or who cannot tolerate, omalizumab. The primary outcome measure for BEACON is incidence and severity of TEAEs and SAEs and secondary outcome measures include UAS7 Score, Urticaria Control Test (UCT) score, and PK and PD measures. The study is being conducted at sites in the US and EU.

Chronic Inducible Urticaria (“CIndU”) is a disorder of mast cells in the skin in which patients experience swelling, redness and itching of the skin that lasts at least six weeks, and is induced by specific physical or environmental stimuli, including cold, heat, exercise, pressure, sunlight and others.

Asthma is a respiratory disease triggered by specific allergens that leads to inflammation constriction of smooth muscles in the airways, cellular infiltration of various immune mediators and excess production of mucus. Patients with asthma may have an increased number of mast cells in the bronchi.

Severe Combined Immunodeficiency Syndrome (“SCID”) is group of genetic disorders characterized by a lack of normal T lymphocyte development, in addition to deficiencies of B cells, NK cells, or both. SCID patients are without a fully functional immune system, which results in chronic infections, failure to thrive and significantly decreased lifespans. If available, these patients are typically given a transplant from a close relative with the goal of allowing healthy donor stem cells to establish in the patient’s bone marrow, leading to production of normal immune cells. However, stem cell transplants are not universally successful. SCID patients with poor transplant outcomes are typically dependent on external therapies such as intravenous immunoglobin and often have poor immunity, leading to chronic infections and decreased lifespans.